Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) was the target of a significant increase in short interest in August. As of August 15th, there was short interest totalling 451,700 shares, an increase of 8.7% from the July 31st total of 415,600 shares. Based on an average trading volume of 45,000 shares, the short-interest ratio is presently 10.0 days. Approximately 7.8% of the company’s stock are sold short.
Analyst Ratings Changes
Separately, HC Wainwright increased their price objective on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, August 23rd.
Read Our Latest Research Report on Greenwich LifeSciences
Greenwich LifeSciences Price Performance
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). On average, research analysts expect that Greenwich LifeSciences will post -0.81 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Snehal Patel bought 5,500 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was purchased at an average cost of $13.18 per share, with a total value of $72,490.00. Following the purchase, the chief executive officer now directly owns 5,532,602 shares of the company’s stock, valued at approximately $72,919,694.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 183,825 shares of company stock worth $2,627,473. Corporate insiders own 52.86% of the company’s stock.
Institutional Trading of Greenwich LifeSciences
Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in Greenwich LifeSciences during the 2nd quarter worth $117,000. Bank of New York Mellon Corp purchased a new position in shares of Greenwich LifeSciences during the second quarter worth about $264,000. Finally, Vanguard Group Inc. increased its position in shares of Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after purchasing an additional 1,420 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.
Greenwich LifeSciences Company Profile
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Articles
- Five stocks we like better than Greenwich LifeSciences
- Do ETFs Pay Dividends? What You Need to Know
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- What Are Trending Stocks? Trending Stocks Explained
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.